-
1 Comment
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 11.8% below its 200 day moving average.
From a valuation standpoint, the stock is 452.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 53.2.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd's total revenue rose by 66.2% to $232M since the same quarter in the previous year.
Its net income has increased by 136.1% to $122M since the same quarter in the previous year.
Finally, its free cash flow grew by 36.4% to $70M since the same quarter in the previous year.
Based on the above factors, Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd gets an overall score of 3/5.
| ISIN | CNE100001R58 |
|---|---|
| Sector | Healthcare |
| Industry | Drug Manufacturers-General |
| CurrencyCode | CNY |
| Exchange | SHE |
| Target Price | 52.56 |
|---|---|
| PE Ratio | 65.34 |
| Beta | 0.43 |
| Market Cap | 25B |
| Dividend Yield | 0.4% |
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and sells pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. It also offers skin care and stem cells series. The company is headquartered in Huzhou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300357.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
